drugset / Trial / NCT01202188

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01202188

Phase 3 Completed 2144 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to provide pivotal efficacy and safety data for QVA149 in patients with moderate to severe COPD.

Timeline

Start
2010-09
Primary completion
2012-02
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Glycopyrronium Unknown 50 ug Inhaled
Comparator Indacaterol Other / unclassified 110 ug Inhaled
Comparator Indacaterol Other / unclassified 150 ug Inhaled
Comparator Tiotropium Other / unclassified 18 ug Inhaled